Results of percutaneous coronary intervention of the unprotected left main coronary artery in 143 patients and comparison of 30-day mortality to results of coronary artery bypass grafting

Am J Cardiol. 2008 Jan 1;101(1):75-81. doi: 10.1016/j.amjcard.2007.07.051. Epub 2007 Nov 26.

Abstract

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery (LMCA) is controversial. In 143 patients who underwent PCI of the unprotected LMCA, 30-day mortality was compared with predicted cumulative risk-adjusted perioperative surgical mortality based on logistic European System for Cardiac Operative Risk Evaluation. One-year clinical follow-up was completed in all patients. The overall major adverse cardiac event rate at 1 year was 34.3%, reflecting the high-risk profile of the patient population. Twelve patients (8%) experienced an acute myocardial infarction and 16 (11%) underwent target lesion revascularization. In 31 patients (22%) who died during the first year, median logistic European System for Cardiac Operative Risk Evaluation was 30%. Calculated RRs showed significantly lower 30-day mortality using PCI compared with predicted surgical mortality (RR 0.54, 95% confidence interval 0.31 to 0.86). Angiographic follow-up in 90 of the 118 patients alive at 6 months showed binary restenosis of 6% in patients treated with drug-eluting stents versus 29% in patients receiving bare-metal stents (p < or =0.01). In conclusion, PCI for unprotected LMCA disease was associated with acceptable short- and medium-term outcomes in patients at low to intermediate risk of bypass surgery. Mortality remains high in very high-risk patients unsuitable for surgery. However, in selected indications, PCI of the LMCA can offer an alternative to surgery, especially when using drug-eluting stents.

Publication types

  • Comparative Study

MeSH terms

  • Acute Coronary Syndrome / therapy
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary*
  • Coronary Artery Bypass*
  • Coronary Artery Disease / mortality*
  • Coronary Artery Disease / therapy*
  • Coronary Restenosis / epidemiology
  • Female
  • Humans
  • Male
  • Myocardial Infarction / epidemiology
  • Outcome Assessment, Health Care
  • Retreatment
  • Risk Adjustment
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives
  • Stents

Substances

  • umirolimus
  • Sirolimus